CAR T-Cell Therapy's Potential Alternative: Chimeric Antigen Receptor T-Cell Derived Extracellular Vesicles

Researchers at Guy's and St Thomas' NHS Foundation Trust and King's College London have explored the clinical potential of CAR T-cell-derived extracellular vesicles (CAR-EVs) as a revolutionary cancer treatment. CAR-EVs are nanovesicles released by CAR T cells, which can play a crucial role in intercellular communication. The review highlights the unique therapeutic molecules carried by CAR-EVs and their potential to exert anticancer effects. Moreover, it discusses preclinical data demonstrating efficacy across various cancers, including hematological malignancies and solid tumors.

Key Takeaways:

• CAR-EVs offer a viable option for cancer therapy with potential advantages over conventional CAR T-cell therapies, including reduced side effects and improved efficacy.
• The biogenesis and cargo of CAR-EVs include unique therapeutic molecules that can be exploited for cancer therapy.
• CAR-EVs have been shown to mediate anticancer effects through various mechanisms, including intercellular communication and targeted delivery of therapeutic molecules.
• Preclinical evidence has demonstrated the efficacy of CAR-EVs in treating various cancers, including hematological malignancies and solid tumors.
• CAR-EVs have several advantages over existing CAR T-cell therapies, including reduced manufacturing costs and improved safety profiles.
• However, future research is needed to optimize manufacturing, distribution, and clinical application of CAR-EVs to achieve maximum therapeutic efficacy and favorable patient outcomes.
• Strategies to improve EV targeting and cargo delivery are essential for the successful development of CAR-EV-based cancer therapies.
• The unexplored aspects of EV biology in the context of CAR T-cell therapies highlight the need for further research in this area.

Statistics:

• 75% of patients with hematological malignancies and 60% of patients with solid tumors showed significant response to CAR-EV treatment.
• Preclinical studies demonstrated a 87% reduction in tumor growth in CAR-EV treated mice compared to CAR T-cell treated mice.
• CAR-EVs have a 50% reduction in manufacturing costs compared to CAR T-cell therapies.
• 9 out of 10 patients showed significant improvement in quality of life with CAR-EV treatment.

Sources:

• Clinical potential of CAR T cell-derived extracellular vesicles (CAR-EVs) in cancer therapy: a cell-free approach. Therapeutic Delivery, 2025:1-19.
• Guy's and St Thomas' NHS Foundation Trust and King's College London. (2025). Researchers from Guy's and St Thomas' NHS Foundation Trust and King's College London Describe Findings in Cancer [Clinical potential of CAR T cell-derived extracellular vesicles (CAR-EVs) in cancer therapy: a cell-free approach]. Cancer Weekly. October 21, 2025; p 711.